FDA approves pirtobrutinib for previously treated CLL/SLLDecember 4, 2023CLLMantle Cell LymphomaMixed TopicsNon-Hodgkin LymphomaIndolent LymphomaB Cell Lymphoma
FDA OKs new agent to block chemotherapy-induced neutropeniaNovember 29, 2023Mixed TopicsAggressive LymphomasB Cell LymphomaDLBCLHodgkin LymphomaIndolent LymphomaMantle Cell Lymphoma
Ocular MALT lymphoma: Radiation reduces relapseOctober 26, 2023B Cell LymphomaIndolent LymphomaMixed Topics
ESMO helps hematologists assess new cancer drugsJune 28, 2023Mixed TopicsCellular TherapyCMLCLLAggressive LymphomasALLAML
Multiprong strategy makes clinical trials less WhiteJune 23, 2023Diversity in MedicinePatient & Survivor CareDLBCLALLAggressive LymphomasAMLB Cell Lymphoma
CBSM phone app eases anxiety, depression in cancer patientsJune 23, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLCLLCML
Huge underuse of germline testing for cancer patientsJune 22, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell LymphomaCellular Therapy
DEI training gives oncology fellows more confidenceJune 22, 2023Diversity in MedicineDLBCLALLAggressive LymphomasAMLB Cell LymphomaCLL
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get medsJune 22, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLAnemiaB Cell Lymphoma
Widespread carboplatin, cisplatin shortages: NCCN surveyJune 9, 2023Patient & Survivor CareMixed TopicsAggressive LymphomasALLAMLB Cell LymphomaCLL
Number of cancer survivors with functional limitations doubled in 20 yearsMay 11, 2023Patient & Survivor CareDiversity in MedicineMixed TopicsDLBCLALLAMLAnemia
‘Exciting’ new gene therapy yields promising resultsJune 5, 2022Gene TherapyIndolent LymphomaB Cell Lymphoma
Ex–hospital porter a neglected giant of cancer researchMay 11, 2022ALLAggressive LymphomasB Cell LymphomaCLLDLBCLMantle Cell LymphomaMultiple Myeloma
FDA investigates possible increased risk of death with lymphoma drugFebruary 4, 2022CLLIndolent Lymphoma
